Thursday, October 20, 2022 8:32:08 AM
October 20 2022 - 07:30AM
GlobeNewswire Inc.
Alert
Share On Facebook
Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company developing antibiotics to treat infections caused by multi-drug resistant pathogens, today announced that the first patient has been dosed in its Phase 3 clinical trial, known as REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales (REASSURE), comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin® (amoxicillin/clavulanate) in adult women with uncomplicated urinary tract infections (uUTI).
“We are pleased to have successfully dosed our first patient in our Phase 3 clinical trial for oral sulopenem for the treatment of uUTI, which is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA),” said Corey Fishman, Chief Executive Officer. “We anticipate completing the trial in the first half of 2024 with our existing cash resources. With positive results, we would resubmit our new drug application (NDA) to the FDA in the second half of 2024.”
About REASSURE
The REASSURE trial is designed as a non-inferiority trial comparing oral sulopenem and Augmentin® in the Augmentin susceptible population and is entitled “A prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability, and safety of oral sulopenem etzadroxil/probenecid versus oral amoxicillin/clavulanate for treatment of uncomplicated urinary tract infections (uUTI) in adult women.” Patients will be randomized to receive either oral sulopenem twice daily for 5 days or Augmentin® twice daily for 5 days. The primary endpoint is the overall response (clinical and microbiologic combined response) at Day 12 of the trial. The trial is expected to enroll approximately 1,966 patients and is being conducted under a SPA agreement with the FDA.
Iterum expects to complete enrollment in the first half of 2024 and, if the Phase 3 clinical trial is successful, resubmit its NDA in the second half of 2024. If the resubmission addresses all deficiencies in the complete response letter received in July 2021 from the FDA, then the FDA’s review and action will occur six months from receipt of the resubmission.
Recent ITRM News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 11:30:38 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:15:13 AM
- Iterum Therapeutics Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/13/2024 11:00:00 AM
- Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024 • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- US Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices Rise • IH Market News • 03/28/2024 11:42:00 AM
- Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 • GlobeNewswire Inc. • 03/21/2024 08:30:00 PM
- Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat • GlobeNewswire Inc. • 03/15/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 01:16:14 PM
- Iterum Therapeutics Provides Business Update • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 10:00:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 12:15:32 PM
- Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections • PR Newswire (US) • 01/30/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2023 09:30:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/14/2023 12:45:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/14/2023 12:30:02 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/04/2023 10:15:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/04/2023 10:00:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 01:30:09 PM
- Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule • GlobeNewswire Inc. • 12/04/2023 01:00:00 PM
- Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023 • GlobeNewswire Inc. • 11/07/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 01:00:11 PM
- Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections • GlobeNewswire Inc. • 10/24/2023 12:00:00 PM
- Iterum Therapeutics to Present Data at IDWeek 2023 • GlobeNewswire Inc. • 10/12/2023 01:15:00 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM